
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health has demonstrated robust financial growth with a two-year revenue compound annual growth rate (CAGR) projected at +28% from 2023 to 2025, supported by strong demand in colorectal cancer (CRC), breast cancer, and new monitoring applications. The company has increased its revenue guidance for the Shield liquid biopsy test, reflecting an anticipated 31% year-over-year growth in 2025, while Reveal remains the fastest-growing oncology test with notable year-over-year test volume increases. Additionally, the continued expansion of reimbursement coverage and new product launches, such as Reveal Ultra, further bolster Guardant Health's long-term revenue growth and margin expectations, enhancing its attractiveness to potential investors.
Bears say
Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, suggesting challenges ahead in meeting growth expectations. The company reported an adjusted EBITDA loss of $45.5 million in the third quarter of 2025, indicating continuing financial strain. Additionally, potential regulatory setbacks, reimbursement issues, and timing problems with product launches may negatively affect the stock's performance, highlighting the fragility of Guardant's growth prospects in a competitive market.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares